Pharma sector outlook: ICRA pegs 7-9% revenue growth for FY26, US headwinds cloud prospects
India’s pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, ...
`Indian pharma resilient to potential US tariffs’
India Ratings and Research (Ind-Ra) anticipates minimal credit profile impact on Indian pharma companies from potential US tariffs on pharmaceutical imports. While the US accounts ...
